Baseline characteristics of patients
| Patient characteristics . | N = 39* . |
|---|---|
| Sex | |
| Male | 20 (51%) |
| Female | 19 (49%) |
| Age at transplant, y (median, range) | 34 (21-67) |
| Institution, N (%) | |
| DFCI/BWH | 19 (49) |
| Mayo Clinic | 3 (8) |
| MSKCC | 3 (8) |
| University of Bologna | 4 (10) |
| Humanitas Clinical & Research Center | 9 (23) |
| Chaim Sheba | 1 (3) |
| Disease, N (%) | |
| Classical HL | 31 (79) |
| DLBCL | 2 (5) |
| FL | 2 (5) |
| PMBCL | 2 (5) |
| EATL | 1 (3) |
| MCL | 1 (3) |
| Total number of systemic treatments (median, range) | 4 (2-8) |
| Radiation therapy, N (%) | 25 (64) |
| Prior autologous transplant, N (%)t | 32 (82) |
| Number of cycles of PD-1 inhibitor (median, range) | 8 (3-27) |
| PD-1 inhibitor received, N (%) | |
| Nivolumab† | 28 (72) |
| Pembrolizumab | 11 (28) |
| Best response to PD-1 inhibitor, N (%) | |
| Complete response | 14 (36) |
| Partial response | 10 (26) |
| Stable disease | 7 (18) |
| Progressive disease | 8 (21) |
| Number of patients with immune-related adverse events while on PD-1 inhibitor (prior to transplant), N (%) | 4 (11) |
| Colitis | 2 (6) |
| Pneumonitis | 2 (6) |
| Hepatitis | 1 (3) |
| Uveitis | 1 (3) |
| Interval between last PD-1 treatment and HSCT (d) | 62 (7-260) |
| Patients with intervening salvage therapy between PD-1 and HSCT, N (%) | 19 (49) |
| Graft source, N (%) | |
| PB | 28 (72) |
| BM | 11 (28) |
| Donor type, N (%) | |
| MRD | 9 (23) |
| MUD | 12 (31) |
| Haploidentical transplant | 14 (36) |
| MMUD‡ | 4 (10) |
| Disease status at allogeneic transplant, N (%) | |
| Complete response | 25 (64) |
| Partial response | 11 (28) |
| Stable disease | 2 (5) |
| Progressive disease | 1 (3) |
| Conditioning regimen, N (%) | |
| RIC | 38 (97) |
| Cy, Flu, TBI | 13 (33) |
| Bu, Flu | 11 (28) |
| Flu, Mel | 5 (13) |
| TT, CY, Flu, ATG | 4 (10) |
| TT, CY, Flu, TBI | 2 (5) |
| TT, Flu, Mel | 2 (5) |
| TT, Flu | 1 (3) |
| MAC | 1 (3) |
| Bu, Flu | 1 (3) |
| GVHD prophylaxis, N (%) | |
| PTCY | 7 (18) |
| PTCY, Tacrolimus, MMF | 7 (18) |
| Tacrolimus, Sirolimus, MTX | 6 (15) |
| Tacrolimus and MTX | 6 (15) |
| CSA, MTX | 5 (13) |
| Other§ | 8 (21) |
| Patient characteristics . | N = 39* . |
|---|---|
| Sex | |
| Male | 20 (51%) |
| Female | 19 (49%) |
| Age at transplant, y (median, range) | 34 (21-67) |
| Institution, N (%) | |
| DFCI/BWH | 19 (49) |
| Mayo Clinic | 3 (8) |
| MSKCC | 3 (8) |
| University of Bologna | 4 (10) |
| Humanitas Clinical & Research Center | 9 (23) |
| Chaim Sheba | 1 (3) |
| Disease, N (%) | |
| Classical HL | 31 (79) |
| DLBCL | 2 (5) |
| FL | 2 (5) |
| PMBCL | 2 (5) |
| EATL | 1 (3) |
| MCL | 1 (3) |
| Total number of systemic treatments (median, range) | 4 (2-8) |
| Radiation therapy, N (%) | 25 (64) |
| Prior autologous transplant, N (%)t | 32 (82) |
| Number of cycles of PD-1 inhibitor (median, range) | 8 (3-27) |
| PD-1 inhibitor received, N (%) | |
| Nivolumab† | 28 (72) |
| Pembrolizumab | 11 (28) |
| Best response to PD-1 inhibitor, N (%) | |
| Complete response | 14 (36) |
| Partial response | 10 (26) |
| Stable disease | 7 (18) |
| Progressive disease | 8 (21) |
| Number of patients with immune-related adverse events while on PD-1 inhibitor (prior to transplant), N (%) | 4 (11) |
| Colitis | 2 (6) |
| Pneumonitis | 2 (6) |
| Hepatitis | 1 (3) |
| Uveitis | 1 (3) |
| Interval between last PD-1 treatment and HSCT (d) | 62 (7-260) |
| Patients with intervening salvage therapy between PD-1 and HSCT, N (%) | 19 (49) |
| Graft source, N (%) | |
| PB | 28 (72) |
| BM | 11 (28) |
| Donor type, N (%) | |
| MRD | 9 (23) |
| MUD | 12 (31) |
| Haploidentical transplant | 14 (36) |
| MMUD‡ | 4 (10) |
| Disease status at allogeneic transplant, N (%) | |
| Complete response | 25 (64) |
| Partial response | 11 (28) |
| Stable disease | 2 (5) |
| Progressive disease | 1 (3) |
| Conditioning regimen, N (%) | |
| RIC | 38 (97) |
| Cy, Flu, TBI | 13 (33) |
| Bu, Flu | 11 (28) |
| Flu, Mel | 5 (13) |
| TT, CY, Flu, ATG | 4 (10) |
| TT, CY, Flu, TBI | 2 (5) |
| TT, Flu, Mel | 2 (5) |
| TT, Flu | 1 (3) |
| MAC | 1 (3) |
| Bu, Flu | 1 (3) |
| GVHD prophylaxis, N (%) | |
| PTCY | 7 (18) |
| PTCY, Tacrolimus, MMF | 7 (18) |
| Tacrolimus, Sirolimus, MTX | 6 (15) |
| Tacrolimus and MTX | 6 (15) |
| CSA, MTX | 5 (13) |
| Other§ | 8 (21) |
ATG, antithymocyte globulin; BM, bone marrow; Bu, busulfan; Chaim Sheba, Chaim Sheba Medical Center in Ramat Gan, Israel; CSA, cyclosporine; CY, cyclophosphamide; DLBCL, diffuse large B-cell lymphoma; EATL, enteropathy-associated T-cell lymphoma; FL, follicular lymphoma; Flu, fludrabine; MAC, myeloablative conditioning; MCL, mantle cell lymphoma; Mel, melphalan; MMF, mycophenolate mofetil; MMUD, mismatched-unrelated donor; MRD, matched-related donor; MSKCC, Memorial Sloan Kettering Cancer Center; MTX, methotrexate; MUD, matched-unrelated donor; PB, peripheral blood; PMBCL, primary mediastinal B-cell lymphoma; PTCY, posttransplant cyclophosphamide; TBI, total body irradiation; TT, thiotepa; University of Bologna, Hematology Institute “L. e A. Seragnoli” at the University of Bologna.
Percentages may not add to 100 because of rounding.
Among those, 4 patients received nivolumab in combination with ipilimumab.
One permissive DR mismatch; 1 DQ mismatch, and unidirectional HvG mismatch.
One patient received a GVHD regimen that included a single dose of ATG. No patients received alemtuzumab.